Long-Term Prognosis of Cerebral Vein and Dural Sinus Thrombosis
Ferro J.M. · Lopes M.G. · Rosas M.J. · Ferro M.A. · Fontes J.
Results of the VENOPORT Study
Department of Neurology, Hospital de Santa Maria, Lisboa, Portugal
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The purpose of this study was to analyze the long-term mortality, functional recovery and long-term complications of cerebral vein and dural sinus thrombosis (CVDST) admitted to Portuguese hospitals. A follow-up of symptomatic CVDST admitted to Portuguese hospitals since 1980 was performed. Fifty-one patients (retrospective cases) were re-evaluated during 1996; 91 consecutively admitted patients from 6/1995 to 6/1998 were followed up to 1999. In 1996, 4 (8%) of the retrospective cases had died (3 patients died in the acute phase), 4 (8%) could not be reached, 33 (64%) had recovered completely (Rankin 0 or 1) and 3 (6%) were dependent. The prospective cases had a mean follow-up of 1 year: 6 (7%) patients died in the acute phase, one (1%) died during follow-up, 75 (82%) recovered completely, and only 1 (1%) was dependent. For the prospective cases, worsening after admission (OR = 18.2; 95% CI = 2.9–112.4) and encephalopathy as the presenting syndrome (OR = 7.1; 95% CI = 1.2–40.9) predicted death or dependency, while absence of aphasia (OR 6.7, 95% CI = 1.6–33) and no worsening after admission (OR = 5.9; 95% CI = 1.6–20) predicted total recovery. During follow-up of the prospective cases, 4 (5%) patients had thrombotic events, 8 (10%) patients experienced seizures, 9 (11%) complained of severe headaches and 1 patient suffered severe visual loss. The long-term functional prognosis of patients with CVDST was fairly good with complete recovery in the majority of cases. However, these patients had a moderate risk of further thrombotic events and seizures.
© 2002 S. Karger AG, Basel
Preter M, Tzourio CH, Ameri A, Bousser MG: Long-term prognosis in cerebral venous thrombosis: A follow-up of 77 patients. Stroke 1996;27:243–246.
Rondepierre P, Hamon M, Leys D, Lederc X, Mournier-Vehrer F, Godefroy O, Janssens E, Pruvo JP: Thromboses veineuses cérébrales: étude de l’évolution. Rev Neurol 1995;151:100–104.
De Bruijn SFTM, Budde M, Teunisse S, de Haan RJ, Stam J, for the CVST Study Group: Long-term outcome of cognition and functional health in cerebral venous sinus thrombosis. Neurology 2000;54:1687–1689.
Bousser MG: Cerebral venous thrombosis: Nothing, heparin, or local thrombolysis? Stroke 1999;30:481–483.
Ferro JM, Correia M, Pontes C, Baptista MV, Pita F, for the Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport): Cerebral vein and dural sinus thrombosis in Portugal: 1980–1998. Cerebrovasc Dis 2001;11:177–182.
Bousser MG, Russell RR: Cerebral venous thrombosis; in Warlow CP, Van Gijn J (eds): Major Problems in Neurology. London, Saunders, 1997, vol 33, pp 27–29, 104–126.
Rankin J: Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scot Med J 1957;ii:200–215.
The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349:1569–1581.
Parmar MKB, Machin D: Survival Analysis: A Practical Approach. Chichester, Wiley, 1995.
Rasmussen BK, Jensen R, Schroll M, Olesen J: Epidemiology of headache in a general population: A prevalence study. J Clin Epidemiol 1991;44:1147–1157.
Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF: A Canadian population survey on the clinical, epidemiologic and social impact of migraine and tension-type headaches. Can J Neurol Sci 1992;19:333–339.
de Bruijn SFTM, Stam J, for the Cerebral Venous Sinus Thrombosis Study Group: Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999;30:484–488.
Lamy C, Hamon JB, Costa J, Mas JL, for the French Study Group on Stroke in Pregnancy: Ischemic stroke in young women: Risk of recurrence during subsequent pregnancies. Neurology 2000;55:269–274.
Nagpal RD: Dural sinus and cerebral venous thrombosis. Neurosurg Rev 1983;6:155–160.
Purvin V, Trobe J, Komorsky G: Neuro-ophthalmic features of cerebral venous obstruction. Arch Ophthalmol 1995;52:880–885.
Biousse V, Ameri A, Bousser M-G: Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology 1999;53:1537–1542.
Ferro JM, Stam J, Barinagarrementeria F, Bousser MG, Einhäupl AB for the ISCVT Collaborators: International Study on Cerebral Venous Thrombosis (ISCVT). Cerebrovasc Dis 1999;9(suppl 1):108. www.ISCTV.com.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.